| DC48009 |
DCLX069 |
DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6. DCLX069 has anticancer effects. |
|
| DC48075 |
SGC-SMARCA-BRDVIII
Featured
|
SGC-SMARCA-BRDVIII is a potent and selective SMARCA2/4 BRD inhibitor. |
|
| DC48137 |
HDAC-IN-26 |
HDAC-IN-26 is a highly selective class I HDAC inhibitor with an EC50 value of 4.7 nM. |
|
| DC48138 |
SKLB325 |
SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) . |
|
| DC48139 |
NVS-BET-1
Featured
|
NVS-BET-1 is a BET bromodomain inhibitor that regulates keratinocyte plasticity. |
|
| DC48140 |
I-CBP112 hydrochloride |
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin. |
|
| DC48141 |
GSK232 |
GSK232 is a highly selective, cellularly penetrant CECR2 inhibitor with excellent physicochemical properties. |
|
| DC48142 |
Amredobresib |
Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1). |
|
| DC48399 |
Procainamide |
Procainamide is a specific and potent inhibitor of DNA methyltransferase 1 (DNMT1). Procainamide is a Class 1A antiarrhythmic agent. Procainamide has the potential for the research of cancer and arrhythmias. |
|
| DC48410 |
CPTH2 hydrochloride |
CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B). |
|
| DC48411 |
CTB
Featured
|
CTB is a p300 activator and the lowest docked energy for CTB and p300 is 7.72 kcal/mol. |
|
| DC48412 |
CPI-1328 |
CPI-1328 is an EZH2 inhibitor with a Ki value of 63 fM. |
|
| DC48413 |
PRMT5-IN-15 |
PRMT5-IN-15 is a PRMT5 inhibitor with an IC50 value of 0.84 nM. |
|
| DC48414 |
EZH2-IN-6 |
EZH2-IN-6 is an EZH2 inhibitor with enhanced antitumor activity. |
|
| DC48431 |
ODM-207 |
ODM-207 is a potent and selective BET inhibitor that is structurally unrelated to the benzodiazepine. ODM-207 also shows potent antiproliferative effects in patient-derived cancer cells and in xenograft models. |
|
| DC48525 |
Phenylbutyrate |
Phenylbutyrate is a potent histone deacetylases (HDACs) inhibitor. Phenylbutyrate can be used for urea cycle disorder research. |
|
| DC48751 |
Cas9-IN-3 |
Cas9-IN-3 is a potent Cas9 inhibitor (IC50=28 μM). CRISPR/Cas systems have revolutionized gene editing in various species. |
|
| DC48761 |
XP5 |
XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma. |
|
| DC48768 |
HDAC6-IN-3 |
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC50s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC50=0.79 μM) and LSD1 inhibitor. |
|
| DC48789 |
HDAC-IN-32 |
HDAC-IN-32 is a potent HDAC inhibitor with IC50s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity. |
|
| DC48792 |
SIRT1 activator 3 |
SIRT1 activator 3 is a potent activator of Sirt1 and suppresses TNF-α in a dose-dependent manner. SIRT1 activator 3 has the potential for anti-obesity or anti-diabetic researches. |
|
| DC48818 |
BRD4-BD1/2-IN-1 |
BRD4-BD1/2-IN-1 is a potent BRD4 inhibitor with IC50s of <100 nM for BRD4 BD-1 and BRD4 BD-2, respectively (US20150148375A1, compound 5). |
|
| DC48829 |
LW479 |
LW479, a novel HDAC inhibitor, could be a candidate drug for breast cancer prevention. |
|
| DC48837 |
HDAC-IN-33 |
HDAC-IN-33 is a potent HDAC inhibitor with IC50s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity. |
|
| DC48868 |
YF479 |
YF479, a novel HDAC inhibitor, displays more potent anti-tumor activity in vitro and in vivo compared with hydroxamic acid (SAHA). |
|
| DC48886 |
Y08175 |
Y08175 is a potent CBP bromodomain inhibitor. Y08175 exhibits considerable inhibitory effect with IC50s of 37 and 178.15 nM against CBP bromodomain in AlphaScreen assay and HTRF assay, respectively. Y08175 can be used for the research of prostate cancer. |
|
| DC48905 |
HDAC-IN-28 |
HDAC-IN-28, a novel HDAC inhibitor, shows potent activities against tumor growth and metastasis |
|
| DC48906 |
ZL0590 |
ZL0590 is a potent, orally active BRD4 BD1-selective inhibitor with an IC50 of 90 nM for human BRD4 BD1. ZL0590 exhibits significant anti-inflammatory activities. |
|
| DC48908 |
WW437 |
WW437 is a histone deacetylase (HDAC) inhibitor with potent anti-breast cancer ability in vitro and in vivo. |
|
| DC48994 |
Y08284 |
Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity. |
|
